CA
NZ
UK
AU
IND
US
Orchestra BioMed Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing the entry into an underwriting agreement and the closing of an underwritten public offering of common stock that generated approximately $86.3 million in gross proceeds.
Andrew Lawrence Taylor, Chief Financial Officer of Orchestra BioMed Holdings, Inc., filed a Form 4 on November 9, 2026, disclosing the purchase of 1,000 shares of common stock at $5.00 per share in an underwritten public offering.
David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), filed a Form 4 on November 9, 2026, disclosing the purchase of 5,000 shares of common stock in an underwritten public offering at $5.00 per share.
Director David Pacitti filed a Form 4 with the SEC on November 9, 2026, disclosing the purchase of 20,000 shares of Orchestra BioMed Holdings, Inc. common stock at $5.00 per share in an underwritten public offering.
Director Eric S. Fain filed a Form 4 with the SEC on November 9, 2026, disclosing a purchase of 20,000 shares of Orchestra BioMed Holdings, Inc. common stock at $5.00 per share through an underwritten public offering.
Michael Gunnar Knell, SVP, Finance and Chief Accounting Officer of Charles River Laboratories International, Inc., filed a Form 4 on November 9, 2026, disclosing a disposition of 649 shares of common stock on November 6, 2026, to satisfy tax withholding obligations tied to the …
Russel Harold McMeekin, Global Corporate President of OpenWorld, Inc. (NASDAQ:OPNW), filed a Form 4 on November 9, 2026, disclosing a stock option amendment transaction dated November 5, 2026, in which an outstanding option was canceled and replaced with a new option at a revised …
Christopher Lawrence Bennett, Chief Legal Officer of Six Flags Entertainment Corporation, filed a Form 4 on November 9, 2026, disclosing an open-market purchase of common stock on November 6, 2026.
Gerard Albert Palana Hernandez, Chief Financial Officer of OpenWorld, Inc. (NASDAQ:OPNW), filed a Form 4 on November 9, 2026, disclosing a stock option amendment and his current beneficial ownership of company securities as of November 5, 2026.
Director Timothy S. Cabral filed a Form 4 with the SEC on November 9, 2026, reporting transactions in Doximity, Inc. (NYSE:DOCS) Class A and Class B Common Stock dated November 5, 2026.
Please wait processing your request...